Eevia Health Plc, ("Eevia" or "The Company"), has received a 21 KEUR sales order from its Australian distributor Ingredients Plus for a new product made from Lingonberry, after a new customer has decided to launch a new product with the Lingonberry ingredient as a key component.
The end customer, which is new to Eevia, is a major natural health company based out of Sydney, Australia selling its consumer products across Oceania. The sales value to Eevia of this new order is c. 21 000 EUR. The product is a Lingonberry extract that contains bioactive proanthocyanidins, a bioactive compound often referred to in the nutraceutical industry called PACs. Eevia's distributor, Ingredients Plus, serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients.
The Lingonberry powder from Eevia is produced for the first time using Gum Arabic Acacia in the spray drying process, which provides an additional unique selling point. Gum Arabic is based on high molecular polysaccharides obtained from the stems and branches of Acacia bushes. It allows customers to use an ingredient without the use of maltodextrin, which is unpopular in consumer groups focused on organic products.
"Although this is only a small start order which takes less than a day to produce, I am extremely excited to see that we are succeeding in developing sales of the Lingonberry products and to reach new customers. The Lingonberry from northern Sweden and Finland is just an amazing raw material source. The Arctic Lingonberry has numerous unique properties. It has natural anti-microbial effects, and high concentrations of proanthocyanidins, two more than the four proanthocyanidins you get from Cranberry. This evergreen plan provides a very stable biomass of fruit year after year. The Swedish and Finnish forests produce more than a million tons of Lingonberries. We are picking only a tiny fraction of that. It tastes good, looks good with vibrant red color, and with its strong health benefits, we have the potential to cannibalize a large cranberry market and also other segments with a superior product" says Stein Ulve, CEO of Eevia Health.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Telephone: +358 400 22 5967
Gabriella Beni, CFO, Eevia Health Plc
Telephone: +358 407 48 8666
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, Chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
The Board of Directors of Eevia Health Plc ("Eevia" or the "Company") has today decided on a rights issue with preferential rights for Eevia's existing shareholders ("Rights Issue"). The target amount is approximately SEK 21.6 million. The proceeds shall primarily finance sales and marketing efforts and increase working capital. About 82 percent of the Rights Issue is covered by subscription and guarantee commitments.
Following a successful quality audit by Eevia Health Plc's ("Eevia" or "The Company") French auditor Natural Ingredients, Eevia has received an 85 KEUR sales order for Bilberry extract from its distributor.
Eevia Health Plc, ("Eevia" or "The Company"), has received a 20 KEUR sales order from a new Finnish customer.
Eevia Health Plc, ("Eevia" or "The Company"), has received a 96 KEUR sales order from a European nutraceutical brand owner.
Eevia Health Plc ("Eevia" or "The Company") is welcoming Dr. Tommi Kilpeläinen asits new Scientific Product Manager.
The Extraordinary General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on October 11, 2022 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:
Authorizing the Board of Directors to decide on the issuance of shares, options, and other special rights
Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 11 October 2022 at 12:00 (Finnish time GMT +3) at the main office of Eevia Health Abp in Koulukatu 14, Seinäjoki, Finland.
The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 11:00.
Eevia Health Plc, ("Eevia" or "The Company"), has received two small starting sales orders from South Korea and Taiwan, totaling approx. 24 KEUR for organically certified bilberry extracts.
Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the second quarter of 2022.
Eevia Health Plc ("Eevia" or "The Company") is welcoming Tuomas Jylhä as interim Chief Financial Officer. Gabriella Beni has decided to leave the Company for personal reasons to focus on private matters. Eevia wishes her the very best in her future endeavors. Tuomas Jylhä will take over the position on July 26th.